---
layout: default
title: Mannitol
description: "Mannitol çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 102
evidence_level: L1
indication_count: 10
---

# Mannitol

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Mannitol (ç”˜éœ²é†‡) - è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Mannitol å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Mannitol ç‚ºæ»²é€æ€§åˆ©å°¿åŠ‘ï¼ŒTxGNN é æ¸¬å…¶å¯ç”¨æ–¼å¤šç¨®ç½•è¦‹ç–¾ç—…å¦‚æƒ¡æ€§é«˜ç†±ã€é€±æœŸæ€§éº»ç—ºåŠè…æºæ€§å°¿å´©ç—‡ç­‰ï¼Œéƒ¨åˆ†é æ¸¬æœ‰æ–‡ç»æ”¯æŒ (ä½è¡€é‰€é€±æœŸæ€§éº»ç—º L3)ï¼Œå…¶ä»–ç‚ºç´”é æ¸¬éšæ®µ (L5)ã€‚
</p>

---

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Mannitol (ç”˜éœ²é†‡ã€æœ¨å¯†é†‡) |
| DrugBank ID | DB00742 |
| å°ç£å•†å“å | ä¿¡æ±ç¾ç«‹å¦¥ã€æ»¿ä¹ƒé€šã€æ¿Ÿç”Ÿé‚å°¼å¦¥ç­‰ |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | åˆ©å°¿ã€é™é¡±å…§å£“ã€è…¦æ°´è…«ã€ä¿ƒé€²æ¯’ç‰©æ’é™¤ã€è…å°çƒéæ¿¾é€Ÿç‡æ¸¬å®š |
| é æ¸¬æ–°é©æ‡‰ç—‡ | nephrogenic syndrome of inappropriate antidiuresisã€congestive heart failureã€acute pulmonary heart diseaseã€exercise-induced malignant hyperthermiaã€malignant hyperthermia, susceptibility toã€familial periodic paralysisã€hypokalemic periodic paralysisã€congenital multicore myopathy with external ophthalmoplegiaã€moderate multiminicore disease with hand involvementã€pseudotumor cerebri |
| TxGNN é æ¸¬åˆ†æ•¸ | 0.997-0.999 |
| è­‰æ“šç­‰ç´š | **L3** (ä½è¡€é‰€é€±æœŸæ€§éº»ç—º)ã€**L5** (å…¶ä»– - åƒ…é æ¸¬æˆ–æ–‡ç»è–„å¼±) |
| è‡¨åºŠè©¦é©— | ç„¡ç›´æ¥ç›¸é—œ |
| PubMed æ–‡ç» | éƒ¨åˆ†æœ‰ |

---





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. nephrogenic syndrome of inappropriate antidiuresis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.97%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>### æ©Ÿè½‰æ¨è«–</p>

<ol>
<li><strong>æ»²é€æ€§åˆ©å°¿ä½œç”¨</strong>ï¼šMannitol ç‚ºæ»²é€æ€§åˆ©å°¿åŠ‘ï¼Œå¯å¢åŠ è¡€æ¼¿æ»²é€å£“ï¼Œä¿ƒé€²æ°´åˆ†å¾çµ„ç¹”è½‰ç§»è‡³è¡€ç®¡å…§ï¼Œä¸¦å¢åŠ è…è‡Ÿæ°´åˆ†æ’æ³„ã€‚</li>

<li><strong>å„é æ¸¬é©æ‡‰ç—‡åˆ†æ</strong>ï¼š</li>

</ol>
<table>
<thead>
<tr>
<th>é æ¸¬é©æ‡‰ç—‡</th>
<th>æ©Ÿè½‰é—œè¯æ€§</th>
<th>èªªæ˜</th>
</tr>
</thead>
<tbody>
<tr>
<td>è…æºæ€§æŠ—åˆ©å°¿ä¸ç•¶ç—‡å€™ç¾¤ (NSIAD)</td>
<td>ä½</td>
<td>æ­¤ç‚ºéºå‚³æ€§ V2 å—é«”çªè®Šï¼ŒMannitol ç†è«–ä¸Šå¯å°æŠ—æ°´åˆ†æ»¯ç•™ï¼Œä½†éæ ¹æœ¬æ²»ç™‚</td>
</tr>
<tr>
<td>æ€¥æ€§è‚ºå¿ƒç—…</td>
<td>ä¸­</td>
<td>æœ‰æ–‡ç»æ”¯æŒ Mannitol å¯é™ä½è‚ºè¡€ç®¡é˜»åŠ›ï¼Œä½†éæ¨™æº–æ²»ç™‚</td>
</tr>
<tr>
<td>æƒ¡æ€§é«˜ç†±</td>
<td>ä½-ä¸­</td>
<td>æ–‡ç»æåŠ Mannitol ä½œç‚ºè¼”åŠ©æ²»ç™‚ä½¿ç”¨ï¼Œä½† Dantrolene ç‚ºé¦–é¸</td>
</tr>
<tr>
<td>å®¶æ—æ€§é€±æœŸæ€§éº»ç—º</td>
<td>ä¸­</td>
<td>ä½œç‚ºéœè„ˆè¼¸æ³¨æº¶åŠ‘ï¼Œé¿å…è‘¡è„ç³–èª˜ç™¼ç™¼ä½œ</td>
</tr>
<tr>
<td>ä½è¡€é‰€é€±æœŸæ€§éº»ç—º</td>
<td>ä¸­-é«˜</td>
<td><strong>æœ‰æ–‡ç»ç›´æ¥æ”¯æŒ</strong>ä½œç‚º KCl éœè„ˆçµ¦è—¥çš„æº¶åŠ‘</td>
</tr>
<tr>
<td>è…æºæ€§å°¿å´©ç—‡</td>
<td>ä½</td>
<td>æ©Ÿè½‰ä¸åˆç†ï¼Œå¯èƒ½åŠ é‡è„«æ°´</td>
</tr>
<tr>
<td>King-Denborough ç—‡å€™ç¾¤</td>
<td>ä½</td>
<td>èˆ‡æƒ¡æ€§é«˜ç†±ç›¸é—œçš„ç½•è¦‹ç–¾ç—…</td>
</tr>
</tbody>
</table>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>ç›®å‰ç„¡é‡å°æ­¤ç‰¹å®šé©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚</p>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26706473/" target="_blank">26706473</a></td><td>2016</td><td>Article</td><td>European journal of internal m</td><td>Ten common pitfalls in the evaluation of patients with hyponatremia.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. acute pulmonary heart disease</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.88%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ7 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05502653" target="_blank">NCT05502653</a></td><td>N/A</td><td>RECRUITING</td><td>100</td><td>Relationship of Fungal Translocation, Inflammation, and Pulmonary Function in HI...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04640168" target="_blank">NCT04640168</a></td><td>PHASE3</td><td>COMPLETED</td><td>1010</td><td>A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and E...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05565430" target="_blank">NCT05565430</a></td><td>N/A</td><td>COMPLETED</td><td>24</td><td>Vocal Cord Responses During Hyperventilation in Normal Individuals and in Mild a...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02927431" target="_blank">NCT02927431</a></td><td>PHASE2</td><td>TERMINATED</td><td>10</td><td>A Phase II, Global, Randomized Study to Evaluate the Efficacy and Safety of Dani...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04492475" target="_blank">NCT04492475</a></td><td>PHASE3</td><td>COMPLETED</td><td>969</td><td>A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and E...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01108744" target="_blank">NCT01108744</a></td><td>NA</td><td>WITHDRAWN</td><td>0</td><td>Double Blind Study of Hypertonic Saline vs Mannitol in the Management of Increas...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04401579" target="_blank">NCT04401579</a></td><td>PHASE3</td><td>COMPLETED</td><td>1033</td><td>A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and E...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ6 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18636060/" target="_blank">18636060</a></td><td>2009</td><td>Article</td><td>Minerva anestesiologica</td><td>Diuretics in acute kidney injury.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25539792/" target="_blank">25539792</a></td><td>2014</td><td>Article</td><td>Trials</td><td>Detailed statistical analysis plan for the pulmonary protection trial.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36990700/" target="_blank">36990700</a></td><td>2023</td><td>Article</td><td>Zhonghua jie he he hu xi za zh</td><td>[Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/324415/" target="_blank">324415</a></td><td>1977</td><td>Article</td><td>Annals of surgery</td><td>Hypertonic mannitol in the therapy of the acute respiratory distress syndrome.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16106599/" target="_blank">16106599</a></td><td>2005</td><td>Article</td><td>Prescrire international</td><td>Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/981097/" target="_blank">981097</a></td><td>1976</td><td>Article</td><td>Postgraduate medical journal</td><td>Pulmonary oedema during treatment of acute water intoxication.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. exercise-induced malignant hyperthermia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.86%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. malignant hyperthermia, susceptibility to</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.80%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ3 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33863282/" target="_blank">33863282</a></td><td>2021</td><td>Article</td><td>BMC anesthesiology</td><td>Malignant hyperthermia when dantrolene is not readily available.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1148076/" target="_blank">1148076</a></td><td>1975</td><td>Article</td><td>British journal of anaesthesia</td><td>Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15637010/" target="_blank">15637010</a></td><td>1995</td><td>Article</td><td>International journal of obste</td><td>Effect of dantrolene sodium on contractility of isolated human uterine muscle.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. familial periodic paralysis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.75%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ2 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18426576/" target="_blank">18426576</a></td><td>2008</td><td>Article</td><td>Journal of translational medic</td><td>Practical aspects in the management of hypokalemic periodic paralysis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32585385/" target="_blank">32585385</a></td><td>2020</td><td>Article</td><td>World neurosurgery</td><td>First-Onset Hypokalemic Periodic Paralysis Following Surgery for Myxopapillary E...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. hypokalemic periodic paralysis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.72%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ3 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32585385/" target="_blank">32585385</a></td><td>2020</td><td>Article</td><td>World neurosurgery</td><td>First-Onset Hypokalemic Periodic Paralysis Following Surgery for Myxopapillary E...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18426576/" target="_blank">18426576</a></td><td>2008</td><td>Article</td><td>Journal of translational medic</td><td>Practical aspects in the management of hypokalemic periodic paralysis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6412669/" target="_blank">6412669</a></td><td>1983</td><td>Article</td><td>Archives of neurology</td><td>Intravenous treatment of hypokalemic periodic paralysis.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. congenital multicore myopathy with external ophthalmoplegia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.72%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. moderate multiminicore disease with hand involvement</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.71%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. nephrogenic diabetes insipidus</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.70%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ2 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4723655/" target="_blank">4723655</a></td><td>1973</td><td>Article</td><td>Radiology</td><td>Azotemia and nephrogenic diabetes insipidus after arteriography.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/13677953/" target="_blank">13677953</a></td><td>2003</td><td>Article</td><td>No to hattatsu = Brain and dev</td><td>[Lithium intoxication in a patient with severe motor and intellectual disabiliti...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. King-Denborough syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.69%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

### è¨±å¯è­‰ç‹€æ…‹ (ç²¾é¸æœ‰æ•ˆè¨±å¯è­‰)

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | æ¿ƒåº¦ | æŒè­‰å•† | æ•ˆæœŸ |
|-----------|--------|------|--------|------|
| å…§è¡›è—¥è£½å­—ç¬¬012343è™Ÿ | ä¿¡æ± ç¾ç«‹å¦¥æ³¨å°„åŠ‘ | 20% | ä¿¡æ±ç”ŸæŠ€ | 2028/05/25 |
| è¡›ç½²è—¥è£½å­—ç¬¬009633è™Ÿ | æ»¿ä¹ƒé€šæ³¨å°„æ¶² | 20% | ææ—æ–°ç”Ÿè£½è—¥ | 2028/05/10 |
| è¡›ç½²è—¥è£½å­—ç¬¬013354è™Ÿ | æ¿Ÿç”Ÿé‚å°¼å¦¥æ³¨å°„æ¶² | 20% | æ¿Ÿç”Ÿé†«è—¥ç”ŸæŠ€ | 2028/05/25 |
| è¡›ç½²è—¥è£½å­—ç¬¬043768è™Ÿ | æ»¿ä¹ƒé€šæ³¨å°„æ¶² | 15% | ææ—æ–°ç”Ÿè£½è—¥ | 2030/05/26 |

### æ ¸å‡†é©æ‡‰ç—‡

1. **åˆ©å°¿**
2. **é™é¡±å…§å£“**
3. **è…¦æ°´è…«**
4. **ä¿ƒé€²æ¯’ç‰©ä¹‹å°¿ä¸­æ’é™¤**
5. **è…å°çƒéæ¿¾é€Ÿç‡ä¹‹æ¸¬å®šï¼ˆè¨ºæ–·ç”¨ï¼‰**
6. **é™ä½çœ¼å£“**
7. **é˜²æ­¢æº¶è¡€**

---

## å®‰å…¨æ€§è€ƒé‡

### è—¥ç‰©äº¤äº’ä½œç”¨ (DDI)

#### åš´é‡ (Major) äº¤äº’ä½œç”¨

| ä½µç”¨è—¥ç‰© | å½±éŸ¿èªªæ˜ |
|---------|---------|
| Amikacin | å¢å¼·è€³æ¯’æ€§èˆ‡è…æ¯’æ€§é¢¨éšª |
| å…¶ä»–æ°¨åŸºç³–è‹·é¡æŠ—ç”Ÿç´  | å¢å¼·è€³æ¯’æ€§èˆ‡è…æ¯’æ€§é¢¨éšª |

#### ä¸­åº¦ (Moderate) äº¤äº’ä½œç”¨

| ä½µç”¨è—¥ç‰©é¡åˆ¥ | ä»£è¡¨è—¥ç‰© | å½±éŸ¿ |
|-------------|---------|------|
| æŠ—å‡è¡€åŠ‘ | Lamivudine | å¯èƒ½å½±éŸ¿è—¥ç‰©æ’æ³„ |
| beta-2 ä¿ƒæ•ˆåŠ‘ | Salbutamol, Formoterol | ä½è¡€é‰€é¢¨éšª |
| ACE æŠ‘åˆ¶åŠ‘ | Captopril, Benazepril | é›»è§£è³ªç•°å¸¸é¢¨éšª |
| ç€‰åŠ‘ | Bisacodyl | é›»è§£è³ªæµå¤±åŠ åŠ‡ |
| æŠ—ç™²ç™‡è—¥ | Carbamazepine | ä½è¡€éˆ‰é¢¨éšªå¢åŠ  |
| SSRI | Citalopram | ä½è¡€éˆ‰é¢¨éšªå¢åŠ  |
| é¡¯å½±åŠ‘ | Diatrizoate, Iothalamic acid | è…æ¯’æ€§é¢¨éšª |
| ç¥ç¶“è‚Œè‚‰é˜»æ–·åŠ‘ | Cisatracurium | é›»è§£è³ªå½±éŸ¿ç¥ç¶“è‚Œè‚‰åŠŸèƒ½ |
| SGLT2 æŠ‘åˆ¶åŠ‘ | Canagliflozin | é›»è§£è³ªç•°å¸¸èˆ‡æ»²é€æ€§åˆ©å°¿åŠ æˆ |

### é‡è¦è­¦èª

1. **é«”æ¶²èˆ‡é›»è§£è³ªå¤±è¡¡**ï¼š
   - å¯å°è‡´åš´é‡è„«æ°´èˆ‡é›»è§£è³ªç´Šäº‚
   - éœ€ç›£æ¸¬è¡€æ¸…é›»è§£è³ªã€æ»²é€å£“ã€è…åŠŸèƒ½

2. **å¾ªç’°è¶…è² è·**ï¼š
   - çµ¦è—¥åˆæœŸå› è¡€æ¼¿æ»²é€å£“å¢åŠ ï¼Œå¯èƒ½å°è‡´è¡€å®¹é‡æ“´å¼µ
   - å¿ƒè‡Ÿè¡°ç«­æ‚£è€…éœ€è¬¹æ…

3. **è…åŠŸèƒ½**ï¼š
   - å¯èƒ½å°è‡´æ€¥æ€§è…æå‚·
   - è…åŠŸèƒ½ä¸å…¨è€…éœ€èª¿æ•´åŠ‘é‡æˆ–é¿å…ä½¿ç”¨

4. **é¡±å…§å‡ºè¡€é¢¨éšª**ï¼š
   - è…¦å¤–å‚·æ‚£è€…è‹¥è¡€è…¦å±éšœç ´æï¼Œå¯èƒ½åŠ é‡è…¦æ°´è…«

### ç¦å¿Œç—‡

- ç„¡å°¿
- åš´é‡è„«æ°´
- é€²è¡Œæ€§å¿ƒè¡°ç«­
- æ´»å‹•æ€§é¡±å…§å‡ºè¡€ï¼ˆé™¤æ‰‹è¡“ä¸­ä½¿ç”¨å¤–ï¼‰
- åš´é‡è‚ºæ°´è…«æˆ–å……è¡€

### ç‰¹æ®Šæ—ç¾¤

- **å­•å©¦**ï¼šCategory Cï¼Œæ¬Šè¡¡åˆ©å¼Šä½¿ç”¨
- **å“ºä¹³å©¦å¥³**ï¼šè³‡æ–™ä¸è¶³ï¼Œè¬¹æ…ä½¿ç”¨
- **è…åŠŸèƒ½ä¸å…¨**ï¼šå¯èƒ½éœ€é¿å…ä½¿ç”¨æˆ–æ¸›é‡
- **è€å¹´äºº**ï¼šéœ€å¯†åˆ‡ç›£æ¸¬é«”æ¶²ç‹€æ…‹

---


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Dehydration** ğŸŸ¡ Moderate
- å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Dehydration** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### è—¥å¸«è©•ä¼°

| é æ¸¬é©æ‡‰ç—‡ | é æ¸¬å¯ä¿¡åº¦ | æ©Ÿè½‰åˆç†æ€§ | è­‰æ“šç­‰ç´š | å»ºè­°å„ªå…ˆåº¦ |
|-----------|-----------|-----------|---------|-----------|
| ä½è¡€é‰€é€±æœŸæ€§éº»ç—º | é«˜ | é«˜ | **L3** | å»ºè­°è¿½è¹¤ |
| æƒ¡æ€§é«˜ç†± | ä½ | ä½ (åƒ…è¼”åŠ©) | L5 | ä¸å»ºè­° |
| è…æºæ€§æŠ—åˆ©å°¿ä¸ç•¶ç—‡å€™ç¾¤ | ä¸­ | ä¸­ | L5 | å¯è€ƒæ…®ç ”ç©¶ |
| æ€¥æ€§è‚ºå¿ƒç—… | ä½ | ä¸­ | L5 | ä¸å»ºè­° |
| è…æºæ€§å°¿å´©ç—‡ | ä½ | ä½ | L5 | ä¸å»ºè­° |
| é€±æœŸæ€§éº»ç—ºå®¶æ—æ€§ | é«˜ | é«˜ | L3 | å»ºè­°è¿½è¹¤ |

### å»ºè­°

1. **ä½è¡€é‰€é€±æœŸæ€§éº»ç—º** (å»ºè­°è¿½è¹¤)ï¼š
   - **è‡¨åºŠæ‡‰ç”¨åƒ¹å€¼æ˜ç¢º**ï¼šä½œç‚ºéœè„ˆè£œå…… KCl çš„æº¶åŠ‘
   - **é‡è¦æé†’**ï¼šç¦ç”¨è‘¡è„ç³–æº¶æ¶²ç¨€é‡‹ KCl
   - å¯ç´å…¥é†«é™¢è™•æ–¹å»ºè­°æˆ–è‡¨åºŠæŒ‡å¼•

2. **æƒ¡æ€§é«˜ç†±** (ä¸å»ºè­°å„ªå…ˆæ¢ç´¢)ï¼š
   - Mannitol åƒ…ç‚ºè¼”åŠ©æ”¯æŒæ²»ç™‚
   - **Dantrolene ç‚ºé¦–é¸æ²»ç™‚**
   - ç„¡éœ€é‡å°æ­¤é©æ‡‰ç—‡é€²è¡Œè€è—¥æ–°ç”¨

3. **å…¶ä»–é æ¸¬é©æ‡‰ç—‡** (ä¸å»ºè­°)ï¼š
   - è…æºæ€§å°¿å´©ç—‡ï¼šæ©Ÿè½‰ä¸åˆç†ï¼Œå¯èƒ½æœ‰å®³
   - æ€¥æ€§è‚ºå¿ƒç—…ï¼šè­‰æ“šéæ–¼è€èˆŠä¸”ä¸è¶³

4. **è—¥å¸«è‡¨åºŠæé†’**ï¼š
   - ä½è¡€é‰€é€±æœŸæ€§éº»ç—ºæ‚£è€…è‹¥éœ€éœè„ˆè£œé‰€ï¼Œå»ºè­°ä½¿ç”¨ **Mannitol æˆ–ç”Ÿç†é£Ÿé¹½æ°´**ç¨€é‡‹ï¼Œ**é¿å…è‘¡è„ç³–æº¶æ¶²**

### è­‰æ“šç­‰ç´šèªªæ˜

- **L3 (ä½è¡€é‰€é€±æœŸæ€§éº»ç—º)**ï¼šæœ‰å¤šç¯‡æ–‡ç»ç›´æ¥æ”¯æŒä½¿ç”¨ Mannitol ä½œç‚º KCl éœè„ˆçµ¦è—¥çš„æº¶åŠ‘
- **L5 (å…¶ä»–é©æ‡‰ç—‡)**ï¼šåƒ…æœ‰é–“æ¥æ–‡ç»æåŠæˆ–ç´”ç²¹é æ¸¬ï¼Œç¼ºä¹ç›´æ¥è‡¨åºŠè­‰æ“š

---

*æœ¬ç­†è¨˜ç”± TxGNN è€è—¥æ–°ç”¨é æ¸¬ç³»çµ±ç”Ÿæˆï¼Œåƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚*

*ç”Ÿæˆæ—¥æœŸï¼š2026-02-11*

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Pitavastatin]({{ "/drugs/pitavastatin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Buprenorphine]({{ "/drugs/buprenorphine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Inclisiran]({{ "/drugs/inclisiran/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Warfarin]({{ "/drugs/warfarin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Levamisole]({{ "/drugs/levamisole/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Mannitolè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/mannitol/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_mannitol,
  title = {Mannitolè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/mannitol/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
